Jefferies Financial Group started coverage on shares of Generation Bio (NASDAQ:GBIO) in a report published on Tuesday morning, BenzingaRatingsTable reports. The brokerage issued a buy rating and a $38.00 price objective on the stock. Jefferies Financial Group also issued estimates for Generation Bio’s Q2 2020 earnings at ($1.10) EPS, Q3 2020 earnings at ($0.51) EPS, Q4 2020 earnings at ($0.61) EPS, FY2020 earnings at ($2.95) EPS, FY2021 earnings at ($2.46) EPS, FY2022 earnings at ($2.25) EPS, FY2023 earnings at ($2.63) EPS and FY2024 earnings at ($2.70) EPS.
Shares of GBIO opened at $19.71 on Tuesday. Generation Bio has a 1 year low of $18.51 and a 1 year high of $24.90.
In other Generation Bio news, insider James E. Flynn purchased 225,000 shares of Generation Bio stock in a transaction dated Tuesday, June 16th. The shares were acquired at an average price of $19.00 per share, with a total value of $4,275,000.00.
Generation Bio Co develops gene therapies for the treatment of genetic diseases. It focuses in the areas of liver, eye, muscle, and brain disorders. Generation Bio Co was formerly known as Torus Therapeutics, Inc and changed its name to Generation Bio Co in November 2017. The company was founded in 2016 and is based in Cambridge, Massachusetts.
Recommended Story: Limitations of the P/E Growth ratio
Receive News & Ratings for Generation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generation Bio and related companies with MarketBeat.com's FREE daily email newsletter.